Facebook
X
LinkedIn
ForwardLiquid Biopsies in Cancer (PRO 04)
Liquid biopsy technologies, particularly circulating tumor DNA (ctDNA), are an emerging tool in precision oncology with growing relevance in radiation oncology. This activity focuses on the current and near-term clinical applications of ctDNA, including noninvasive tumor genotyping, early cancer detection, and minimal residual disease (MRD) monitoring. Expert physician-scientists present recent data that highlight the strengths, limitations, and practical considerations for using liquid biopsy in clinical workflows.
Target Audience
This activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, diagnostic radiologists, pathologists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand the basics regarding circulating tumor DNA (ctDNA) and liquid biopsy technologies and applications.
- Understand the utility of ctDNA for noninvasive genotyping, early cancer detection, and minimal residual disease detection and monitoring.
- Aadel A. Chaudhuri, MD, PhD, is employed by Mayo Clinic Rochester. Dr. Chaudhuri receives compensation/payment from AlphaSights, AstraZeneca, Daiichi Sankyo, DeciBio, Guidepoint, Illumina, Roche and Tempus Labs. Dr. Chaudhuri owns stock in Geneoscopy. Dr. Chaudhuri has ownership equity in Droplet Biosciences and LiquidCell Dx, Inc.
- Scott V. Bratman, MD, PhD, is employed by Princess Margaret Cancer Centre, University Health Network and Adela, Inc. Dr. Bratman owns a copyright/patent with Adela, Inc and Roche.
- Maximilian Diehn, MD, PhD, is employed by Stanford Cancer Institute and Kaiser Permanente. Dr. Diehn receives honoraria, salary support and grant/research funding from AstraZeneca. Dr. Diehn receives honoraria and owns stock options in Gritstone Bio. Dr. Diehn has ownership equity in CiberMed, Foresight Diagnostics and Perception Medicine. Dr. Diehn receives royalties from a patent with Roche.
- Abhijit A. Patel, MD, PhD, is employed by Yale University School of Medicine. Dr. Patel receives compensation/payment from NuProbe and Biostate AI. Dr. Patel owns equity, copyright/patent/royalties and stock in Binary Genomics and receives grant/research funding from AstraZeneca.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.